IDEXX Laboratories, Inc. $IDXX Shares Sold by Brasada Capital Management LP

Brasada Capital Management LP trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,859 shares of the company’s stock after selling 1,426 shares during the quarter. IDEXX Laboratories accounts for approximately 3.3% of Brasada Capital Management LP’s portfolio, making the stock its 5th biggest position. Brasada Capital Management LP’s holdings in IDEXX Laboratories were worth $19,335,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IDXX. Elyxium Wealth LLC acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $3,666,459,000. Northwestern Mutual Wealth Management Co. grew its position in IDEXX Laboratories by 63,503.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after acquiring an additional 1,442,174 shares in the last quarter. Norges Bank acquired a new position in IDEXX Laboratories in the 4th quarter valued at about $332,265,000. Arrowstreet Capital Limited Partnership grew its position in IDEXX Laboratories by 197.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 550,368 shares of the company’s stock valued at $372,340,000 after acquiring an additional 365,274 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in IDEXX Laboratories by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after acquiring an additional 326,348 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.5%

IDXX stock opened at $560.88 on Friday. The company’s 50 day moving average is $563.06 and its two-hundred day moving average is $627.69. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.24 billion, a P/E ratio of 41.30, a PEG ratio of 3.07 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the business posted $2.91 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on IDXX. UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.